| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Y Hu, H Yamamoto, M Sohmiya, T Abe, Y Murakami, Y Kat. Body composition assessed by bioelectrical impedance analysis (BIA) and the correlation with plasma insulin-like growth factor I (IGF-I) in normal Japanese subjects and patients with acromegaly and GH deficiency. Endocrine journal. vol 41. issue 1. 1994-12-20. PMID:7951554. |
percent body cell mass (bcm/bw) was higher in acromegaly and lower in gh deficiency than in normals. |
1994-12-20 |
2023-08-12 |
human |
| P Nyquist, E R Laws, E Elliot. Novel features of tumors that secrete both growth hormone and prolactin in acromegaly. Neurosurgery. vol 35. issue 2. 1994-12-20. PMID:7969823. |
the most prominent previously reported clinical features of growth hormone (gh) and prolactin (prl)-secreting pituitary adenomas associated with acromegaly have included the high incidence of galactorrhea in women and a generally more favorable response to dopamine agonist therapy. |
1994-12-20 |
2023-08-12 |
human |
| L Fredstorp, S Werner, P Bang, K Hal. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide. Clinical endocrinology. vol 41. issue 4. 1994-12-19. PMID:7525123. |
we have investigated whether this inverse relation also exists in acromegaly, before and during treatment with octreotide, and whether changes in igfbp-1 levels relate to gh and igf-i levels. |
1994-12-19 |
2023-08-12 |
Not clear |
| T B Hansen, J Gram, P Bjerre, C Hagen, J Bollersle. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clinical endocrinology. vol 41. issue 3. 1994-12-19. PMID:7955439. |
we have studied changes in body composition during short-term reduction in gh level by octreotide in active acromegaly. |
1994-12-19 |
2023-08-12 |
Not clear |
| A Ogo, M Haji, S Natori, T Kanzaki, Y Kabayama, R Y Osamura, H Nawata, H Ibayash. Acromegaly with hyperprolactinemia developed after bilateral adrenalectomy in a patient with Cushing's syndrome due to adrenocortical nodular hyperplasia. Endocrine journal. vol 40. issue 1. 1994-11-29. PMID:7951491. |
the patient was a rare case of acromegaly with hyperprolactinemia developed after bilateral adrenalectomy of cushing's syndrome due to adrenocortical nodular hyperplasia, all of which manifestations may be caused by a gh, prl and acth secreting pituitary adenoma. |
1994-11-29 |
2023-08-12 |
Not clear |
| A Giustina, A R Bussi, M Doga, C Iacobello, W B Wehrenber. Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 26. issue 6. 1994-11-23. PMID:7927192. |
the aims of our study were to investigate the effect of the acetylcholinesterase inhibitor pyridostigmine (pd) administration on growth hormone (gh) secretion in acromegaly and to investigate the effects of pd on gh levels following an i.v. |
1994-11-23 |
2023-08-12 |
Not clear |
| A Liuzzi, G Oppizzi, R Cozzi, D Dallabonzana, M Petroncini, P Orlandi, P G Chiodin. GH regulation in acromegaly. The Journal of pediatric endocrinology. vol 6. issue 3-4. 1994-11-10. PMID:7921003. |
gh regulation in acromegaly. |
1994-11-10 |
2023-08-12 |
Not clear |
| W Saeger, M J Puchner, D K Lüdeck. Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing's disease. A report of 3 cases. Virchows Archiv : an international journal of pathology. vol 425. issue 1. 1994-11-10. PMID:7921420. |
two patients who showed acromegaly and hyperprolactinaemia had a gangliocytoma and a growth hormone (gh)-prolactin cell adenoma in close proximity. |
1994-11-10 |
2023-08-12 |
Not clear |
| P Chanson, A Dib, A Visot, P J Derom. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. European journal of endocrinology. vol 131. issue 3. 1994-11-01. PMID:7921205. |
in the sole patient who could be operated on, a typical adenoma with positive immunostaining for gh was incompletely removed and postoperative radiation therapy failed to cure the acromegaly. |
1994-11-01 |
2023-08-12 |
Not clear |
| C J Strasburge. Implications of investigating the structure-function relationship of human growth hormone in clinical diagnosis and therapy. Hormone research. vol 41 Suppl 2. 1994-10-19. PMID:7522207. |
improvements in understanding the structure-function relationship of the human gh molecule and of the interplay of the hormone with its receptor make it conceivable that recombinant analogues of human gh will be designed to inhibit the effects of gh excess in acromegaly. |
1994-10-19 |
2023-08-12 |
human |
| M L Hartman, S M Pincus, M L Johnson, D H Matthews, L M Faunt, M L Vance, M O Thorner, J D Veldhui. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. The Journal of clinical investigation. vol 94. issue 3. 1994-10-13. PMID:8083369. |
pulses of growth hormone (gh) release in acromegaly may arise from hypothalamic regulation or from random events intrinsic to adenomatous tissue. |
1994-10-13 |
2023-08-12 |
human |
| M L Hartman, S M Pincus, M L Johnson, D H Matthews, L M Faunt, M L Vance, M O Thorner, J D Veldhui. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. The Journal of clinical investigation. vol 94. issue 3. 1994-10-13. PMID:8083369. |
daily gh secretion rates, calculated by deconvolution analysis, were greater in patients with active acromegaly than in fed (p < 0.05) but not fasted normal subjects. |
1994-10-13 |
2023-08-12 |
human |
| M L Hartman, S M Pincus, M L Johnson, D H Matthews, L M Faunt, M L Vance, M O Thorner, J D Veldhui. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. The Journal of clinical investigation. vol 94. issue 3. 1994-10-13. PMID:8083369. |
we conclude that gh secretion in acromegaly is highly irregular with disorderly release accompanying significant basal secretion. |
1994-10-13 |
2023-08-12 |
human |
| Y Greenman, S Melme. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. The Journal of clinical endocrinology and metabolism. vol 79. issue 3. 1994-10-06. PMID:7521350. |
sstr5 is expressed predominantly in mammosomatotroph-derived tumors, suggesting that this receptor subtype may be an important determinant of gh secretion in acromegaly. |
1994-10-06 |
2023-08-12 |
Not clear |
| K Hanew, A Utsumi, A Sugawara, Y Shimizu, H Ikeda, K Ab. The evaluation of hypothalamic somatostatin tone using pyridostigmine and thyrotropin releasing hormone in patients with acromegaly. Journal of endocrinological investigation. vol 17. issue 5. 1994-10-05. PMID:7915736. |
to indirectly evaluate the hypothalamic somatostatin (ss) tone in patients with acromegaly, the effects of pyridostigmine (pd), a cholinesterase inhibitor which can inhibit hypothalamic ss secretion, on trh-induced tsh secretion and the effects of sms 201-995 on tsh or gh secretion were studied in acromegalic patients (31-69 yr, n = 10), normal young (21-24 yr, n = 7) and normal old male subjects (62-71 yr, n = 7). |
1994-10-05 |
2023-08-12 |
human |
| T Gasińska, S Nowa. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly]. Endokrynologia Polska. vol 44. issue 4. 1994-09-13. PMID:8055814. |
usefulness of determination of blood serum prolactin concentration and the result of thyroliberin (trh) stimulation test for predicting the magnitude of growth hormone (gh) response to the administration of sandostatin and bromocriptine has been evaluated in 14 patients with active acromegaly. |
1994-09-13 |
2023-08-12 |
Not clear |
| A Juul, K Main, W F Blum, J Lindholm, M B Ranke, N E Skakkebae. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical endocrinology. vol 41. issue 1. 1994-09-06. PMID:7519529. |
serum levels of igf-i and igfbp-3 decrease with age in normal adults and are elevated in active acromegaly due to excessive gh secretion. |
1994-09-06 |
2023-08-12 |
Not clear |
| L Fredstorp, K Kutz, S Werne. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clinical endocrinology. vol 41. issue 1. 1994-09-06. PMID:8050122. |
several studies suggest that the combination of octreotide and bromocriptine is more effective than octreotide alone in reducing gh levels in patients with acromegaly. |
1994-09-06 |
2023-08-12 |
Not clear |
| K Y Ho, A J Weissberge. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical endocrinology. vol 41. issue 1. 1994-09-06. PMID:8050134. |
early studies of acromegaly undertaken before the general availability of insulin-like growth factor i (igf-i) assays have used arbitrary and varying growth hormone (gh) threshold levels for diagnosing and assessing outcome of treatment for this disease. |
1994-09-06 |
2023-08-12 |
Not clear |
| K Y Ho, A J Weissberge. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clinical endocrinology. vol 41. issue 1. 1994-09-06. PMID:8050134. |
we have undertaken a detailed study of gh secretion and its relationship to igf-i levels to assess the usefulness of gh and igf-i measurements in the assessment of acromegaly. |
1994-09-06 |
2023-08-12 |
Not clear |